Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 901–1,000 of 1,001
Novel strategies for treating relapsed/refractory urothelial carcinoma
Iyer, G., Milowsky, M. I., & Bajorin, D. F. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.182 · Cited by 18
Zaniani, N. R., Oroujalian, A., Valipour, A., & Peymani, M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06623-3 · Cited by 17
Ouchi, K., Takahashi, S. I., Okita, A., Sakamoto, Y., Muto, O., Amagai, K., Okada, T., Ohori, H., Shinozaki, E., & Ishioka, C. (2021) · Cancer Science · doi:10.1111/cas.15252 · Cited by 18
The emerging era of personalized medicine in advanced colorectal cancer
Wu, C. W., Reid, M., Leedham, S. J., & Lui, R. N.-S. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15937 · Cited by 21
Research advances in nanomedicine applied to the systemic treatment of colorectal cancer
Yin, L., Li, H., Shi, L., Chen, K., Pan, H., & Han, W. (2022) · International Journal of Cancer · doi:10.1002/ijc.34256 · Cited by 19
Lin, J.-K., Lin, A.-J., Lin, C., Lan, Y., Yang, S., Li, A. F., & Chang, S. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21993 · Cited by 19
Fede, G. D., Bronte, G., Rizzo, S., Rolfo, C. D., Cocorullo, G., Gulotta, G., Bazan, V., & Russo, A. D. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.594436 · Cited by 17
Zhang, L., Ma, L., & Zhou, Q. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1197-5 · Cited by 20
Chew, H. K., Somlo, G., Mack, P. C., Gitlitz, B. J., Gandour‐Edwards, R. F., Christensen, S. M., Linden, H. M., Solis, L. J., Yang, X., & Davies, A. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr328 · Cited by 17
“Single-agent activity has been reported with the use of multiple agents targeting the EGFR pathway including trastuzumab, the monoclonal antibody to HER2 [2]; lapatinib, a tyrosine kinase inhibitor (TKI) of EGRF and HER2 [3]; erlotinib [4, 5] and gefitinib [6], both EGFR TKIs; and cetuximab, the monoclonal antibody to…”
BackgroundLess Than Ideal: How Oncologists Practice With Limited Drug Access
Chan, K., Wong, B., Siu, L. L., Straus, S. E., Chang, J., & Berry, S. R. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000337 · Cited by 17
Self-citationRees, J. R. E., Whale, K., Fish, D. R., Fayers, P. M., Cafaro, V., Pusic, A. L., Blazeby, J. M., & Efficace, F. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1970-x · Cited by 37
Takahashi, N., Yamada, Y., Furuta, K., Nagashima, K., Kubo, A., Sasaki, Y., Shoji, H., Honma, Y., Iwasa, S., Okita, N. T., et al. (2015) · Cancer Science · doi:10.1111/cas.12642 · Cited by 17
Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer
Bai, S., Feng, Q., Pan, X.-Y., Zou, H., Chen, H.-B., Wang, P., Zhou, X., Hong, Y., Song, S., & Yang, J.-L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2903 · Cited by 19
Piryani, S. O., Kam, A. Y. F., Kliassov, E. G., Chen, B. J., Spector, N. L., Chute, J. P., Hsu, D. S., Chao, N. J. A., & Doan, P. L. (2017) · Stem Cells · doi:10.1002/stem.2731 · Cited by 17
Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer
Iemoto, T., Nishiumi, S., Kobayashi, T., Fujigaki, S., Hamaguchi, T., Kato, K., Shoji, H., Matsumura, Y., Honda, K., & Yoshida, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.9731 · Cited by 17
Epidemiology of colorectal cancer
Pitchumoni, C. S., & Broder, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819672-4.00002-7 · Cited by 23
Arai, Y., Aoyama, T., Inaba, Y., Okabe, H., Ihaya, T., Kichikawa, K., Ohashi, Y., Sakamoto, J., Oba, K., & Saji, S. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12324 · Cited by 17
FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer
Chaix, M., Vincent, J., Lorgis, V., & Ghiringhelli, F. (2014) · Oncology · doi:10.1159/000361031 · Cited by 17
Dranitsaris, G., Truter, I., Lubbe, M. S., Sriramanakoppa, N. N., Mendonca, V. M., & Mahagaonkar, S. B. (2011) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646231000125x · Cited by 17
Liao, W., Liao, Y., Zhou, J. X., Xie, J., Chen, J., Huang, W., & Luo, R. (2010) · The Anatomical Record · doi:10.1002/ar.21202 · Cited by 18
“VC 2010 WILEY-LISS, INC. and lung cancer (Jonker et al., 2007; Van Cutsem et al., 2007).”
KRAS mutational testing in the selection of patients for EGFR-targeted therapies
García, J. J., Riely, G. J., Nafa, K., & Ladanyi, M. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.08.003 · Cited by 20
Tronconi, M. C., Sclafani, F., Rimassa, L., Carnaghi, C., Personeni, N., & Santoro, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5651 · Cited by 17
Burudpakdee, C., Zhao, Z., Munakata, J., Gao, S., Trochlil, K., & Barber, B. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.650774 · Cited by 18
Hertogh, G. D., & Geboes, K. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.853 · Cited by 20
Matsunaga, M., Kaneta, T., Miwa, K., Ichikawa, W., Fujita, K., Nagashima, F., Furuse, J., Kage, M., Akagi, Y., & Sasaki, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4576 · Cited by 21
Shitara, K., Yuki, S., Yoshida, M., Takahari, D., Utsunomiya, S., Yokota, T., Sato, Y., Inaba, Y., Tajika, M., Kawai, H., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9615-z · Cited by 17
“Based on past pivotal studies, the standard schedule for cetuximab is weekly administration [1, 2].”
BackgroundMatsumoto, Y., Sakurai, H., Kogashiwa, Y., Kimura, T., Matsumoto, Y., Shionome, T., Asano, M., Saito, K., & Kohno, N. (2016) · Head & Neck · doi:10.1002/hed.24626 · Cited by 17
Iwamoto, S., Ooki, A., Morita, S., Hara, H., Tanioka, H., Satake, H., Kataoka, M., Kotaka, M., Kagawa, Y., Nakamura, M., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1623 · Cited by 18
Jo, S. J., & Kim, S. H. (2019) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.12.10 · Cited by 17
Ramos, F. J., Macarulla, T. M., Capdevila, J., Élez, E., & Tabernero, J. M. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.s.008 · Cited by 19
Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101718 · Cited by 16
“In this study, the eligible patients who met the following inclusion criteria were enrolled: 1) mCRC patients with RAS MT (KRAS/NRAS exon 2, 3, or 4 MT) confirmed in tumor tissues before study enrollment, 2) confirmed refractory or intolerance to previous chemotherapy, including fluoropyrimidines, oxaliplatin, or irin…”
BackgroundMethodGraham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., Hjelmgren, J., Barber, B., & Fakih, M. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.023 · Cited by 16
Self-citationThe association of health-care contact days with physical function and survival in CCTG/AGITG CO.17
Gupta, A., O'Callaghan, C. J., Zhu, L., Jonker, D. J., Wong, R. P. W., Colwell, B., Moore, M. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae077 · Cited by 16
Self-citationDumur, C. I., Idowu, M. O., & Powers, C. N. (2012) · Cancer Cytopathology · doi:10.1002/cncy.21225 · Cited by 16
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
Grothey, A. A., & Yan, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s79145 · Cited by 19
Deeken, J. F., Shimkus, B., Liem, A., Hill, D., Gurtler, J. S., Berghorn, E., Townes, L., Lu, H., Trifan, O. C., & Zhang, S. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2146-5 · Cited by 16
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
Brand, T. M., Dunn, E., Iida, M., Myers, R. A., Kostopoulos, K. T., Li, C., Peet, C. R., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.5.16394 · Cited by 20
Clay, T. M., Osada, T., Hartman, Z. C., Hobeika, A. C., Devi, G. R., Morse, M. A., & Lyerly, H. K. (2010) · Immunologic Research · doi:10.1007/s12026-010-8186-6 · Cited by 16
Rocha‐Lima, C., Marques, E. D. Q., Bayraktar, S., Broome, P., Weissman, C., Nowacki, M. P., Leslie, M., & Susnerwala, S. S. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2520-y · Cited by 16
“additionally, cetuximab has established single-agent efficacy in colon cancer, whereas g17Dt activity in colon cancer as a single agent is unknown [23].”
BackgroundKozuch, P. S., Malamud, S., Wasserman, C., Homel, P., Mirzoyev, T., & Grossbard, M. L. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.006 · Cited by 16
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
Fuloria, J. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s31412 · Cited by 17
Adverse events of targeted therapies
Klastersky, J. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000096 · Cited by 16
EGFR pathway in advanced non-small cell lung cancer
Novello, S. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/s168 · Cited by 16
Novel Drug Therapies in Myeloid Leukemia: a Patent Review
Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 18
Prokineticin 2 expression as a novel prognostic biomarker for human colorectal cancer
Yoshida, Y., Goi, T., Kurebayashi, H., Morikawa, M., Hirono, Y., & Katayama, K. (2018) · Oncotarget · doi:10.18632/oncotarget.25706 · Cited by 20
Yeoh, Y., Low, T. Y., Abu, N., & Lee, P. Y. (2021) · PeerJ · doi:10.7717/peerj.12338 · Cited by 19
Crosnier, A., Abbara, C., Cellier, M., Lagarce, L., Babin, M., Bourneau‐Martin, D., & Briet, M. B. (2021) · Cancers · doi:10.3390/cancers13235907 · Cited by 16
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Li, Y., Yang, C., Gan, Y., Lu, F., & Qin, Y. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-022-07572-8 · Cited by 16
Pryor, D. I., Burmeister, E. A., Burmeister, B. H., Poulsen, M. G., & Porceddu, S. V. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.023 · Cited by 16
Hong, L. P. T., Scoble, J. A., Doughty, L., Coia, G., & Williams, C. C. (2011) · Australian Journal of Chemistry · doi:10.1071/ch11071 · Cited by 16
Zhang, L., Hou, Y., Zhang, J., Hu, J. R., & ZHANG, K. (2013) · Oncology Letters · doi:10.3892/ol.2013.1281 · Cited by 17
Ogasawara, N., Bando, H., Kawamoto, Y., Yoshino, T., Tsuchihara, K., Ohtsu, A., & Esumi, H. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq151 · Cited by 16
Nie, F., Shen, J., Tong, J. L., Xi Tao, X. U., Zhu, M., & Ran, Z. H. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00393.x · Cited by 16
Jung, M.-J., Woo, C. G., Lee, S.-B., Chin, S., Kim, H. K., Kwak, J. J., Koh, E. S., Lee, B., Jang, K., & Moon, A. (2017) · Pathology · doi:10.1016/j.pathol.2017.06.001 · Cited by 16
Alternate dosing of cetuximab for patients with metastatic colorectal cancer.
Hubbard, J. M., & Alberts, S. R. (2013) · Europe PMC (PubMed Central) · Cited by 18
Beyond Exon 2 — The Developing Story of RAS Mutations in Colorectal Cancer
Berlin, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejme1307992 · Cited by 17
The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications
Longo, F., Gattuso, G., Spoto, G., Ricci, D., Vitale, A. C. V., Lavoro, A., Candido, S., Libra, M., & Falzone, L. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.05.012 · Cited by 18
“In the case of wild-type KRAS and BRAF genes, patients can benefit from the FOLFOX/FOLFIRI protocol combined with the anti-EGFR selective inhibitor, named cetuximab [11].”
Vojjala, N., Gibatova, V., Shah, R. N., Singal, S., Prabhu, R. R., Krishnamoorthy, G., Riggins, K. S., & Moka, N. (2025) · Cancers · doi:10.3390/cancers17152520 · Cited by 16
“In the era of precision medicine, which incorporates molecular and environmental information into clinical decision-making, identifying patients harboring a deficiency in DNA repair allowed for targeted immunotherapies and significantly reduced CRC-related mortality [4,5].”
Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response
Sud, S., O’Callaghan, C., Jonker, C., Karapetis, C. S., Price, T. J., Tebbutt, N. C., Shapiro, J. D., van Hazel, G., Pavlakis, N., Gibbs, P., et al. (2018) · Current Oncology · doi:10.3747/co.25.4069 · Cited by 15
Self-citationDiscovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data
Forbes, A. N., Xu, D., Cohen, S. M., Pancholi, P., & Khurana, E. (2024) · Cell Systems · doi:10.1016/j.cels.2024.08.004 · Cited by 15
Tumor Shrinkage and Objective Response Rates
Bradbury, P. A., & Seymour, L. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181b9c506 · Cited by 15
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
Ho, C., Sangha, R. S., Beckett, L. A., Tanaka, M. S., Lau, D. H., Eisen, D. B., Burich, R. A., Luciw, P. A., Khan, I., Mack, P. C., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9396-4 · Cited by 15
Targeted therapy in advanced colorectal cancer: more data, more questions
Ochenduszko, S. L., & Krzemieniecki, K. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833cfc99 · Cited by 16
Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?
Govaert, K. M., van Kessel, C. S., Lolkema, M. P., Ruers, T. J. M., & Rinkes, I. H. M. B. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0122-9 · Cited by 15
Modest, D. P., Reinacher‐Schick, A., Stintzing, S., Giessen, C. A., Tannapfel, A., Laubender, R. P., Brodowicz, T., Knittelfelder, R., Vrbanec, D., Schmiegel, W., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352ff1d · Cited by 17
Next generation of antibody therapy for cancer
Zhu, Z., & Li, Y. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10123 · Cited by 19
Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview
Fan, Y. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0510 · Cited by 18
Perez, K. J., Walsh, R. J., Brilliant, K. E., Noble, L. C., Yakirevich, E., Breese, V., Jackson, C. L., Chatterjee, D. N., Pricolo, V. E., Roth, L. A., et al. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.01.004 · Cited by 18
Colorectal hepatic metastasis: Evolving therapies
Macedo, F. I., & Makarawo, T. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i7.453 · Cited by 20
Wu, H., Liu, C., Xiao-xia, F., Wang, H., & Zhou, L. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170204 · Cited by 17
Scheff, N. N., Ye, Y., Conley, Z. R., Quan, J. W., Lam, Y. V. R., Klares, R., Singh, K., Schmidt, B. L., & Aouizerat, B. E. (2020) · Pain · doi:10.1097/j.pain.0000000000001926 · Cited by 17
“signaling (eg, cetuximab and gefitinib) are currently available to treat cancer.(26,36,54).”
BackgroundCiblage de la voie de signalisation RAS pour le traitement des cancers
Mansi, L., Viel, E., Curtit, E., Médioni, J., & Tourneau, C. L. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1380 · Cited by 21
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000155 · Cited by 17
Marshall, J. L. (2009) · Journal of Oncology · doi:10.1155/2009/937305 · Cited by 18
Shitara, K., Yokota, T., Takahari, D., Shibata, T., Ura, T., Utsunomiya, S., Inaba, Y., Yamaura, H., Sato, Y., Najima, M., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9382-x · Cited by 15
“The frequency of grade 2 skin toxicity in the present study was higher than that observed in previous prospective studies [1, 2], which may reflect the long treatment duration due to positive treatment responses in the wild-type KRAS patients in this study.”
BackgroundMethodResultTargeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins
Shapira, S., Lisiansky, V., Arber, N., & Kraus, S. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003737668 · Cited by 15
Kubo, A., Hashimoto, H., Takahashi, N., & Yamada, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.887 · Cited by 15
Clinical applications of liquid biopsies in gastrointestinal oncology
Zhu, J., & Strickler, J. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.08 · Cited by 16
Watanabe, S., Nakamura, M., Takahashi, H., Hara, M., Ijichi, K., Kawakita, D., & Morita, A. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s140796 · Cited by 15
Li, Z., Chen, Y., Ren, W., Hu, S., Tan, Z.-L., Wang, Y., Chen, Y., Zhang, J., Wu, J., Li, T., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20126 · Cited by 16
Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?
Hanna, T. P., Nguyen, P., Pater, J. L., O'Callaghan, C. J., Mittmann, N., Earle, C. C., Tu, D., Jonker, D. J., & Hay, A. E. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00691 · Cited by 17
Self-citationInhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell
Yang, X., Wang, S., Yu, W., Zheng, Y., & Wu, Y. (2020) · Medicine · doi:10.1097/md.0000000000020944 · Cited by 15
“We speculated that inhibition of ITGB1 might be a new therapeutic target of CRC.”
BackgroundInfluentialAsano, J., & Hirakawa, A. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2049 · Cited by 15
“Such subpopulations include epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated lung cancer,(1-3) human epidermal growth factor receptor 2 (HER2)-positive breast cancer,(4,5) and Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer.(6,7) Clinical developments of…”
BackgroundVelho, S., Oliveíra, C., & Seruca, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1525 · Cited by 15
Biomarkers in the development of individualized treatment regimens for colorectal cancer
Crutcher, M. M., & Waldman, S. A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1062423 · Cited by 15
“Cetuximab has been approved as a first-line treatment in mCRC patients with wild-type KRAS in combination with chemotherapy (38).”
BackgroundShash, E., Peccatori, F. A., & Azim, H. A. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.05 · Cited by 14
Kono, S. A., Haigentz, M., Yom, S. S., & Saba, N. F. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/901320 · Cited by 15
How to integrate molecular targeted agents in the continuum of care
Köhne, C.-H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq374 · Cited by 15
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
Lo, L. L., Patel, D., Townsend, A. R., & Price, T. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1112787 · Cited by 15
Self-citationTaniguchi, H., Komori, A., Narita, Y., Kadowaki, S., Ura, T., Andoh, M., Yatabe, Y., Komori, K., Kimura, K., Kinoshita, T., et al. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv193 · Cited by 14
Ota, K., Harada, T., Otsubo, K., Fujii, A., Tsuchiya, Y., Tanaka, K., Okamoto, I., & Nakanishi, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19552 · Cited by 14
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis
Gardini, A. C., Vagheggini, A., Gelsomino, F., Spallanzani, A., Ulivi, P., Orsi, G., Rovesti, G., Andrikou, K., Tamburini, E., Scartozzi, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.10.001 · Cited by 15
Triazole-estradiol analogs: A potential cancer therapeutic targeting ovarian and colorectal cancer
Ostlund, T., Alotaibi, F. S., Kyeremateng, J., Halaweish, H., Kasten, A., Iram, S. H., & Halaweish, F. T. (2021) · Steroids · doi:10.1016/j.steroids.2021.108950 · Cited by 17
Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
André, L., Antherieu, G., Boinet, A., Bret, J., Gilbert, T., Boulahssass, R., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14102470 · Cited by 15
Hameedat, F., Pizarroso, N. A., Teixeira, N., Pinto, S. F. T., & Sarmento, B. F. C. C. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106259 · Cited by 14
Translational research of new developments in targeted therapy of colorectal cancer
Yang, L., Atakhanova, N. E., Arellano, M. T. C., Mohamed, M. Y., Hani, T., Fahdil, A. A., Castillo-Acobo, R. Y., Juyal, A., Hussein, A. K., Amin, A. H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154888 · Cited by 16
Ogata, Y., Shimokawa, M., Tanaka, T., Emi, Y., Oki, E., Saeki, H., Sadanaga, N., Kusumoto, T., Touyama, T., Kimura, M., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0895-3 · Cited by 14
Pearce, A. M., Haas, M. R., & Viney, R. C. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0058-5 · Cited by 16
“8 % at the less serious grade I or II [64].”
BackgroundTumour Genetics and Genomics to Personalise Cancer Treatment
Voon, P. J., & Kong, H. L. (2011) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v40n8p362 · Cited by 18
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.